TMEM130: A Potential Drug Target for Various Diseases (G222865)

Target Name: TMEM130

NCBI ID: G222865

TMEM130

TMEM130: A Potential Drug Target for Various Diseases

TMEM130 (Tissue Membrane Efflux (TMEM130) gene) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. TMEM130 is a member of the transmembrane protein (TMEM) family, which are involved in the regulation of cell signaling and signaling pathways.

TMEM130 is a gene that encodes a protein known as TMEM130, which is a protein that is expressed in various tissues and cells of the body. TMEM130 is involved in the regulation of cell signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases, including cancer.

TMEM130 has been shown to be involved in the regulation of TGF-β signaling in various tissues and cells. For example, studies have shown that TMEM130 is involved in the regulation of TGF-β signaling in breast cancer cells. Researchers have found that TMEM130 levels are elevated in breast cancer cells, and that inhibition of TMEM130 has been shown to reduce the growth and survival of these cells.

Another study has shown that TMEM130 is involved in the regulation of TGF-β signaling in neurodegenerative diseases. Researchers have found that TMEM130 is expressed in the brains of individuals with Alzheimer's disease, and that inhibition of TMEM130 has been shown to reduce the neurodegeneration in these individuals.

TMEM130 has also been shown to be involved in the regulation of TGF-β signaling in autoimmune disorders. For example, studies have shown that TMEM130 is involved in the regulation of TGF-β signaling in the development of rheumatoid arthritis. Researchers have found that TMEM130 levels are elevated in individuals with rheumatoid arthritis, and that inhibition of TMEM130 has been shown to reduce the development and progression of these conditions.

In addition to its involvement in TGF-β signaling, TMEM130 has also been shown to be involved in the regulation of other signaling pathways, including the Wnt signaling pathway. This pathway is involved in the regulation of cell growth and survival, and is a key factor in the development and progression of many diseases, including cancer.

TMEM130 has also been shown to be involved in the regulation of cell signaling pathways that are involved in the regulation of cell adhesion and migration. These include the cadherin signaling pathway, which is involved in the regulation of cell-cell adhesion, and the vimentin signaling pathway, which is involved in the regulation of cell-cell migration.

TMEM130 has been shown to be involved in the regulation of many different signaling pathways, including TGF-β, Wnt, cadherin, and vimentin. These signaling pathways are involved in the regulation of cell growth, differentiation, and survival, and are key factors in the development and progression of many diseases.

As a potential drug target or biomarker, TMEM130 is being studied for its potential utility in the treatment of various diseases. For example, studies have shown that inhibition of TMEM130 has been shown to be effective in the treatment of breast cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target or biomarker, TMEM130 has also been shown to be involved in the regulation of cell signaling pathways that are involved in the regulation of cell adhesion and migration. These include the cadherin signaling pathway, which is involved in the regulation of cell-cell adhesion, and the vimentin signaling pathway,

Protein Name: Transmembrane Protein 130

The "TMEM130 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM130 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets